{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:34:33Z","timestamp":1777358073715,"version":"3.51.4"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gonadotropin-releasing hormone agonists (GnRHa) are widely used to treat central precocious puberty (CPP), yet long-term outcomes based on confirmed final adult height (FAH) remain limited, particularly in Asian populations. Whether GnRHa therapy enables patients to surpass their genetically predicted height potential has not been well established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 250 girls with central precocious puberty (CPP) or early puberty treated with depot leuprolide acetate (3.75\u2005mg every 4 weeks) at Chang Gung Memorial Hospital (2003\u20132023). Among 84 patients with confirmed FAH, 73 were included after excluding those receiving growth hormone. Patients were categorized as FAH\u2009&amp;gt;\u2009mid-parental height (MPH) or FAH\u2009\u2264\u2009MPH. Clinical and auxological variables were analyzed, and ROC analysis evaluated the predictive value of age at treatment initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 73 patients, 39 (53.4%) achieved FAH exceeding MPH. These patients were younger at treatment initiation, had greater bone age advancement, and higher baseline height SDS, while absolute height was similar. During therapy, they maintained superior height SDS and growth velocity, resulting in a 6.57\u2005cm greater FAH (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). ROC analysis showed modest discrimination (AUC\u2009\u223c\u20090.69), and no independent predictors were identified on multivariable analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In conclusion, GnRHa therapy is associated with favorable height outcomes in a subset of patients, particularly with earlier initiation and sustained growth during treatment. These findings support a prognostic, individualized approach emphasizing skeletal maturity, pubertal tempo, and longitudinal growth monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1819205","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:37:06Z","timestamp":1777354626000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Surpassing genetic height potential at final adult height after monthly depot leuprolide therapy in Taiwanese girls with central precocious or early puberty: a ROC-based analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Pei-Chi","family":"Lin","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology & Genetics, Department of Pediatrics, Chang Gung Memorial Hospital, Chung Gung University College of Medicine","place":["Taoyuan, Taiwan"]},{"name":"Department of Pediatrics, Chang Gung Memorial Hospital","place":["Chiayi, Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wen","family":"Lai","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology & Genetics, Department of Pediatrics, Chang Gung Memorial Hospital, Chung Gung University College of Medicine","place":["Taoyuan, Taiwan"]},{"name":"Department of Pediatrics, Chiayi Christian Hospital","place":["Chiayi, Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Sung","family":"Lo","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology & Genetics, Department of Pediatrics, Chang Gung Memorial Hospital, Chung Gung University College of Medicine","place":["Taoyuan, Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1056\/NEJMcp0800459","article-title":"Clinical practice. Precocious puberty","volume":"358","author":"Carel","year":"2008","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1210\/js.2019-00036","article-title":"Treatment of central precocious puberty","volume":"3","author":"Eugster","year":"2019","journal-title":"J Endocr Soc"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1210\/jcem.84.6.5647","article-title":"Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of decapeptyl in precocious puberty","volume":"84","author":"Carel","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1210\/jcem.86.10.7915","article-title":"Increased final height in precocious puberty after long-term treatment with LHRH agonists: the national institutes of health experience","volume":"86","author":"Klein","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1530\/eje.0.1410140","article-title":"Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty","volume":"141","author":"Arrigo","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1590\/2359-3997000000144","article-title":"Central precocious puberty: revisiting the diagnosis and therapeutic management","volume":"60","author":"Brito","year":"2016","journal-title":"Arch Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1530\/EJE-08-0814","article-title":"The use of GnRH agonists in precocious puberty","volume":"159","author":"Mul","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1210\/jc.2007-1216","article-title":"Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function","volume":"93","author":"Pasquino","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0022-3476(52)80205-7","article-title":"Tables for predicting adult height from skeletal age: revised for use with the greulich-pyle hand standards","volume":"40","author":"Bayley","year":"1952","journal-title":"J Pediatr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0201906","DOI":"10.1371\/journal.pone.0201906","article-title":"Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1271395","DOI":"10.3389\/fendo.2023.1271395","article-title":"The effects of gonadotropin-releasing hormone agonist on final adult height among girls with early and fast puberty","volume":"14","author":"Tseng","year":"2023","journal-title":"Front. Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e752","DOI":"10.1542\/peds.2008-1783","article-title":"Consensus statement on the use of gonadotropin-releasing hormone analogs in children","volume":"123","author":"Carel","year":"2009","journal-title":"Pediatrics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.17925\/EE.2015.11.01.45","article-title":"Central precocious puberty\u2014management and long-term outcomes","volume":"11","author":"L\u00e9ger","year":"2015","journal-title":"Eur Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1210\/jc.2007-0321","article-title":"Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity","volume":"92","author":"Lazar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.6065\/apem.2014.19.4.214","article-title":"Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone","volume":"19","author":"Jung","year":"2014","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1159\/000542038","article-title":"Adult height in girls with central precocious puberty with onset after 6 years: effects of gonadotropin-releasing hormone analog therapy","volume":"99","author":"Saito","year":"2026","journal-title":"Horm Res Paediatr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/cen.14420","article-title":"Which parameters predict the beneficial effect of GnRHa treatment on height in girls with central precocious puberty?","volume":"94","author":"Vuralli","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3390\/children12060756","article-title":"Final adult height in girls treated with GnRH analogues for precocious puberty around age eight","author":"Bahar Ak\u0131n","year":"2025","journal-title":"Children (Basel)"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1097\/00000441-195909000-00030","volume-title":"Radiographic Atlas of Skeletal Development of the Hand and Wrist","author":"Greulich","year":"1959"},{"key":"B20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1515\/jpem-2022-0476","article-title":"Using change in predicted adult height during GnRH agonist treatment for individualized treatment decisions in girls with central precocious puberty","volume":"36","author":"Trujillo","year":"2023","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.6065\/apem.2017.22.2.95","article-title":"The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty","volume":"22","author":"Kim","year":"2017","journal-title":"Ann Pediatr Endocrinol Metab"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1819205\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:37:07Z","timestamp":1777354627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1819205\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":21,"alternative-id":["10.3389\/fped.2026.1819205"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1819205","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"1819205"}}